BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magro DO, Kotze PG, Martinez CAR, Camargo MG, Guadagnini D, Calixto AR, Vasques ACJ, Ayrizono MLS, Geloneze B, Pareja JC, Saad MJ, Coy CSR. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease.Intest Res. 2017;15:352-357. [PMID: 28670232 DOI: 10.5217/ir.2017.15.3.352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Marlicz W, Skonieczna-Żydecka K, Dabos KJ, Łoniewski I, Koulaouzidis A. Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818769076. [PMID: 29707039 DOI: 10.1177/1756284818769076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
2 Enz N, Vliegen G, De Meester I, Jungraithmayr W. CD26/DPP4 - a potential biomarker and target for cancer therapy. Pharmacol Ther 2019;198:135-59. [PMID: 30822465 DOI: 10.1016/j.pharmthera.2019.02.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
3 Wang T, Yang JY, Buse JB, Pate V, Tang H, Barnes EL, Sandler RS, Stürmer T. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.Diabetes Care. 2019;42:2065-2074. [PMID: 31471377 DOI: 10.2337/dc19-0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Vojdani A, Vojdani E, Herbert M, Kharrazian D. Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA. Int J Mol Sci 2020;21:E1381. [PMID: 32085663 DOI: 10.3390/ijms21041381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
5 Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.BMJ. 2018;360:k872. [PMID: 29563098 DOI: 10.1136/bmj.k872] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 13.8] [Reference Citation Analysis]
6 Verediano TA, Stampini Duarte Martino H, Dias Paes MC, Tako E. Effects of Anthocyanin on Intestinal Health: A Systematic Review. Nutrients 2021;13:1331. [PMID: 33920564 DOI: 10.3390/nu13041331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang J, Liu X, Wei Y, Li X, Gao S, Dong L, Rao X, Zhong J. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Front Immunol 2022;13:830863. [DOI: 10.3389/fimmu.2022.830863] [Reference Citation Analysis]
8 Magro DO, Santos A, Guadagnini D, de Godoy FM, Silva SHM, Lemos WJF, Vitulo N, Torriani S, Pinheiro LV, Martinez CAR, Saad MJA, Coy CSR. Remission in Crohn's disease is accompanied by alterations in the gut microbiota and mucins production. Sci Rep. 2019;9:13263. [PMID: 31520001 DOI: 10.1038/s41598-019-49893-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Fernandes SA, Rossoni C, Koch VW, Imbrizi M, Evangelista-Poderoso R, Pinto LP, Magro DO. Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease. Artif Intell Gastroenterol 2021; 2(4): 111-123 [DOI: 10.35712/aig.v2.i4.111] [Reference Citation Analysis]
10 Zhao Y. CD26 in autoimmune diseases: The other side of "moonlight protein".Int Immunopharmacol. 2019;75:105757. [PMID: 31357088 DOI: 10.1016/j.intimp.2019.105757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol 2021;14:17562848211032126. [PMID: 34377149 DOI: 10.1177/17562848211032126] [Reference Citation Analysis]
12 Magro DO, Barreto MRL, Cazzo E, Camargo MG, Kotze PG, Coy CSR. Visceral fat is increased in individuals with crohn's disease: A comparative analysis with healthy controls.Arq Gastroenterol. 2018;55:142-147. [PMID: 30043863 DOI: 10.1590/S0004-2803.201800000-25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Gorreja F, Caër C, Rush STA, Forsskål SK, Härtlova A, Magnusson MK, Bexe Lindskog E, Börjesson LG, Block M, Wick MJ. MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn´s Disease Patients. Inflammation 2022. [PMID: 35190924 DOI: 10.1007/s10753-022-01647-8] [Reference Citation Analysis]
14 El-Shiekh RA, Hussein D, Atta AH, Mounier SM, Mousa Shiekh MR, Abdel-Sattar E. Anti-inflammatory activity of Jasminum grandiflorum L. subsp. floribundum (Oleaceae) in inflammatory bowel disease and arthritis models. Biomed Pharmacother 2021;140:111770. [PMID: 34119929 DOI: 10.1016/j.biopha.2021.111770] [Reference Citation Analysis]
15 Melo FJ, Pinto-Lopes P, Estevinho MM, Magro F. The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.Inflamm Bowel Dis. 2021;27:1153-1165. [PMID: 33295607 DOI: 10.1093/ibd/izaa324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]